Login / Signup

REMIT-UC: Real World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis.

Christopher MaRemo PanaccioneYasi XiaoYuvan KhandelwalSanjay K MurthyEmily C L WongNeeraj NarulaCatherine TsaiFarhad PeeraniMarica Reise-FilteauBrian BresslerSamantha Y StarkeyDustin LoomesRocio SedanoVipul JairathTalat Bessissow
Published in: The American journal of gastroenterology (2022)
One-third of UC patients treated with tofacitinib achieved clinical remission with few serious adverse events. However, half of patients lost response with de-escalation, which was only partially recaptured with increasing the maintenance dose. Those with negative prognostic factors should be counselled about the risks and benefits of continuing high dose tofacitinib.
Keyphrases